FiercePharma

SANOFI'S NEW BASAL INSULIN LANTUS XR, KNOWN AS TOUJEO IN THE U.S. AND EUROPE, APPROVED IN JAPAN FOR THE TREATMENT OF DIABETES MELLITUS

SANOFI'S NEW BASAL INSULIN LANTUS XR, KNOWN AS TOUJEO IN THE U.S. AND EUROPE, APPROVED IN JAPAN FOR THE TREATMENT OF DIABETES MELLITUS Paris, France - July 3, 2015 - Sanofi announced today that the ...
HeraldNet

Sanofi settles lawsuit enabling rival to Lantus insulin

TRENTON, N.J. — A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over ...
The Motley Fool

Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus

Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (MYL +0.00%) and Biocon's Semglee, which is essentially identical to ...
Business Wire

GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...
JD Supra

Merck’s Lantus Biosimilar Queued for an FDA Submission?

Merck, known as MSD outside the United States and Canada, announced promising results from two Phase III studies evaluating MK-1293 – Merck’s biosimilar to Lantus (insulin glargine). Lantus is used ...
USA Today

3 major insulin makers have now slashed the price of the life-saving drug. Here's why.

Amid consumer angst and political pressure over the cost of life-saving insulin, Sanofi announced Thursday it would slash the price of its most-prescribed insulin, Lantus. Sanofi said it will cut the ...